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0959-8049/ª 2017 Elsevier Ltd. All righAbstract Background: Mammalian target of rapamycin inhibitors may induce pneumonitis.
We analysed the association of pneumonitis with outcomes in everolimus treated metastatic
renal cell carcinoma (mRCC) patients.
Patients and methods: Eighty-five mRCC patients received everolimus at Helsinki University
Hospital (cohort A). Computed tomography (CT) verified pneumonitis was correlated with
outcome using KaplaneMeier, Cox regression and logistic regression. An independent cohort
of 148 everolimus treated mRCC patients (cohort B) at Aarhus University Hospital was as-
sessed for validation.
Results: In cohort A, CT-verified pneumonitis (N Z 29, 34.1%) was associated with improved
overall survival (OS) (24.7 versus 8.5 months; P < 0.001), progression-free survival (PFS) (5.5
versus 3.2 months; P Z 0.002) and clinical benefit rate (CBR) 57.1% versus 24.1%
(P Z 0.003). In multivariate analyses pneumonitis was associated with improved OS (hazard
ratio [HR], 0.22; 95% confidence interval [CI] 0.12e0.44; P < 0.001), PFS (HR 0.37; 95% CI
0.21e0.66; P Z 0.001) and CBR (odds ratio [OR] 4.11; 95% CI 1.42e11.95; P Z 0.01).
In cohort B, CT-verified pneumonitis (N Z 29, 19.6%) was associated with improved OS
(12.9 versus 6.0 months; P Z 0.02), PFS (6.0 versus 2.8 months; P Z 0.02) and CBR
(79.3% versus 39.5%; P < 0.001). In multivariate analyses pneumonitis was associated with
improved OS (HR 0.58; 95% CI 0.36e0.94; P Z 0.03), PFS (HR 0.61; 95% CI 0.39e0.95;
P Z 0.03) and CBR (OR 5.65; 95% CI 2.10e15.18; P Z 0.001).
In a combined multivariate analysis (N Z 233), with pneumonitis as a time-dependent co-




P. Penttilä et al. / European Journal of Cancer 81 (2017) 9e1610P Z 0.03). Furthermore, in a landmark analysis, pneumonitis was associated with longer OS
(17.4 versus 7.8 months; P Z 0.01).
Conclusions: Everolimus-induced pneumonitis is associated with improved outcome in pa-
tients with mRCC and may serve as a biomarker of everolimus efficacy.
ª 2017 Elsevier Ltd. All rights reserved.1. Introduction
Everolimus is an orally administrated inhibitor of
mammalian target of rapamycin (mTOR), which regu-
lates cell growth, proliferation, survival and angiogen-
esis [1]. It is a recommended treatment for patients with
metastatic renal cell carcinoma (mRCC), whose disease
has progressed after initial vascular endothelial growth
factor receptor (VEGFR) therapy, either alone [2], or in
combination with lenvatinib [3]. Other second-line
treatment options are nivolumab [4], cabozantinib [5]
and axitinib [6]. Everolimus has also been approved
for treatment of progressive neuroendocrine tumours
and advanced breast cancer [7e9].
Everolimus has class-specific adverse effects,
including rash, pneumonitis, risk of infection, stomatitis,
fatigue and metabolic changes. Everolimus induced non-
infectious pneumonitis is characterised clinically by
difficulty of breathing, often accompanied by a dry,
non-productive cough and radiologically by non-
specific, non-infectious and non-malignant infiltrates in
the lungs. The reported incidence of pneumonitis during
everolimus treatment varies between 13.5% and 48.7%
[10e12]. The pathogenesis of mTOR-related pneumo-
nitis remains unknown. Suggested mechanisms include a
cell-mediated autoimmune response and T-cellemedi-
ated delayed-type hypersensitivity [13,14]. In two pre-
vious studies involving mRCC patients treated with
mTOR-inhibitors, pneumonitis was a marker of stable
disease (SD) [15] or prolonged survival [16]. The number
of patients treated with everolimus was, however, low
(N Z 25 and N Z 100, respectively) and the studies did
not control for potential time-bias from longer
treatment.
The objective of this study was to evaluate the pre-
dictive and prognostic role of everolimus induced
pneumonitis in consecutive patients with mRCC in two
independent patient cohorts.
2. Materials and methods
2.1. Patients and treatment
A total of 85 consecutive mRCC patients were treated
with everolimus after VEGFR targeted therapy failure
at the Cancer Center, Helsinki University Hospital,
Finland, between October 18, 2006 and December 31,2014 (cohort A). Data collected from the hospital case
records included patient demographic features, treat-
ments given, adverse events, hospitalisations and
outcome data.
A validation series of 148 consecutive patients treated
with everolimus between January 25, 2010 and June 6,
2016 at Aarhus University Hospital, Denmark were
collected (cohort B).
Everolimus was administered according to standard
care until disease progression or unacceptable toxicity.
2.2. Assessment of tumour response and adverse events
Response to treatment was assessed by computed to-
mography at 8e12 week intervals. Treatment efficacy
was reported according to Response Evaluation Criteria
in Solid Tumours version 1.1 (RECIST) [17]. Adverse
events were captured every 4e6 weeks and were graded
according to Common Terminology Criteria for
Adverse Events (CTCAE) version 3.0 [18].
2.3. Assessment of pneumonitis
Medical files, including computed tomography (CT)
scan reports, were retrospectively reviewed for pneu-
monitis and the radiographic studies were subjected to a
blinded review by a radiologist for findings indicative of
pneumonitis. Patients with confirmed radiologic evi-
dence of pneumonitis (graded per CTCAE version 3.0)
were assigned to the CT-verified pneumonitis group
(cohort A). To further evaluate the impact of pneumo-
nitis, patients in cohort B were divided into three
groups: patients with pneumonitis verified by CT
(graded per CTCAE version 3.0), patients with clinical
pulmonary symptoms, but inconclusive radiological
evidence of pneumonitis/pneumonia and patients with
no clinical or radiological signs of pneumonitis/
pneumonia.
2.4. Statistical analysis
The study population consisted of two independent
patient cohorts, cohorts A and B, and they were ana-
lysed separately. The patients’ characteristics were
described overall and by pneumonitis status. Median
follow-up time for patients alive was assessed using
Schemper’s method. The association of pneumonitis and
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neWhitney U test for continuous data and the Chi-
squared test for categorical data. The end-points in the
study were (i) overall survival (OS) defined as the time
from treatment initiation to death, whatever the cause
and (ii) progression-free survival (PFS) defined as the
time from treatment initiation to the first event (tumour
progression or death from any cause) and (iii) clinical
benefit rate (CBR) defined as partial response or SD as
overall best response per RECIST 1.1. The
KaplaneMeier method was used to estimate the median
survival times with 95% confidence intervals (CIs) for
both OS and PFS, censoring the patients who were alive
or had no disease progression at the last follow-up visit.
UnivariateCoxproportional hazardmodel was used to
assess the association between pneumonitis and OS and
PFS in both cohorts separately. The interaction between
pneumonitis and cohort was tested in Cox models
including cohort, pneumonitis and the interaction term as
covariates. Non-significant interaction terms indicated
that the associationbetweenpneumonitis andOSandPFS
was not significantly different in the two cohorts. Multi-
variate analysis for OS and PFS were performed using
Cox proportional hazardmodels adjusted for age, gender,
number of previous treatment lines, Memorial Sloan-
Kettering Cancer Center (MSKCC) risk classification for
previously treated patients (Karnofsky performance
status < 80%, serum haemoglobin  115 g/L for females
and130 g/L for males, corrected calcium 2.5 mmol/L)
[19] and pneumonitis. The results are expressed as hazard
ratios (HRs) with 95% CI. The proportional hazards
assumption was assessed graphically, obtaining plots of
log(elogS(t)) versus time and Schoenfeld residuals versus
time. Minor violations of the proportional hazards were
accepted because the number of patients at risk after 12
months was not adequate to estimate and interpret reli-
ably the plots. Therefore, themodelswere confirmed using
also a shorter follow-up time.
A multivariate logistic regression model was used to
investigate the effects of age, gender, MSKCC risk
classification and pneumonitis on the CBR. The results
are expressed as ORs with 95% CI.
To control for lead-time bias, a time-dependent Cox
regression model, including cohort as a covariate, was
conducted. Additionally, a landmark survival analysis
with the landmark set at 2.5 months after date of initi-
ation of everolimus treatment was applied. To provide
sufficient statistical power, the two patient cohorts were
combined (N Z 233). Per the landmark method, the
analysis included patients who had no events before the
landmark time point. PFS and OS were defined as the
time from the landmark to progression or death from
any cause, and pneumonitis status was assessed ac-
cording to whether pneumonitis had developed up to the
landmark time.
All statistical tests were two-sided and P-
values < 0.05 were considered as statistically significant.Analysis was performed using IBM SPSS Statistics for
Windows (version 24.0, Armonk, NY, USA, IBM
Corp.).3. Results
3.1. Patient characteristics
The study population consisted of two patient cohorts:
cohort A (NZ 85) and a validation cohort B (NZ 148).
Patient characteristics for both groups are shown in
Table 1. Median follow-up time for patients alive was
44.1 months in cohort A and 37.1 months in cohort B.
Median times on everolimus treatment were 2.9 months
(range: 0.4e31.2 months) and 2.8 months (range
0.1e46.3 months), respectively. In cohort A, 66 (77.6%)
patients stopped treatment due to progression and 15
(17.6%) patients due to adverse events (AE). The
remaining four patients (4.7%) continued treatment at
the time of data cut-off. In cohort B, 85 (57.4%) patients
stopped treatment due to progression and 54 (36.5%)
patients without progression (33 AE, 21 other). The
remaining nine patients (6.1%) continued treatment at
the time of data cut-off.
OS and PFS for cohort A were 11.0 months (95% CI
7.3e14.7 months) and 3.5 months (95% CI 3.2e3.9
months), respectively, and 6.7 months (95% CI 5.4e8.1
months) and 2.8 months (95% CI 2.5e3.2 months),
respectively, for cohort B.
Of the patients in cohort A and B, 11.8% and 19.6%,
respectively, received everolimus after three or more
treatment lines.3.2. Pneumonitis and outcome
In cohort A, 29 (34.1%) patients had CT-verified
pneumonitis during everolimus treatment. Eight cases
were grade I (27.6%), 18 cases grade II (62.1%) and three
cases were grade III (10.3%). No grade IV (life-threat-
ening) pneumonitis was recorded. In cohort B, 29
(19.6%) patients had CT-verified pneumonitis. Among
patients with pneumonitis, median time to onset was 2.4
months (range 0.4e7.5 months) in cohort A and 2.8
months (range 0.1e14.1 months) in cohort B.
In univariate analysis, patients with pneumonitis had
longer OS (cohort A: 24.7 versus 8.5 months; P < 0.001;
cohort B: 12.9 versus 6.0 months; P Z 0.02) and PFS
(cohort A: 5.5 versus 3.2 months; P Z 0.002; cohort B:
6.0 versus 2.8 months; P Z 0.02) as compared to pa-
tients with no pneumonitis. KaplaneMeier curves for
OS and PFS are depicted in Fig. 1AeD. As the in-
teractions between cohort and pneumonitis were non-
significant (P Z 0.36 for OS and P Z 0.69 for PFS),
the two patient cohorts were combined. In the combined
data using Cox regression model with cohort as a co-
variate, pneumonitis was significantly associated with
Table 1
Characteristics of patients with and without pneumonitis in cohorts’ A and B.
Cohort A (N Z 85) P Cohort B (N Z 148) P
Pneumonitis Total Pneumonitis Total
No (N Z 56)
(65.9%)
Yes (N Z 29)
(34.1%)
N Z 85 No (N Z 119)
(80.4%)
Yes (N Z 29)
(19.6%)
N Z 148
Gender Male 33 (58.9) 19 (65.5) 52 (61.2) 0.55 84 (70.6) 20 (69.0) 104 (70.3) 0.86
Female 23 (41.1) 10 (34.5) 33 (38.8) 35 (29.4) 9 (31.0) 44 (29.7)
Age Median 66.5 63.0 66.0 0.71 65.0 63.0 64.0 0.27
Range 24e87 48e82 24e87 39e81 40e77 39e81
Karnofsky < 80% Yes 18 (32.1) 7 (24.1) 21 (24.7) 0.44 44 (37.0) 6 (20.7) 50 (33.8) 0.10
No 38 (67.9) 22 (75.9) 64 (75.3) 75 (63.0) 23 (79.3) 98 (66.2)
Prior nephrectomya Yes 44 (78.6) 26 (89.7) 70 (82.4) 0.20 89 (74.8) 27 (93.1) 116 (78.4) 0.03
No 12 (21.4) 3 (10.3) 15 (17.6) 30 (25.2) 2 (6.9) 32 (21.6)
Histology Clear cell 37 (80.4) 25 (96.2) 62 (86.1) 0.06 107 (93.0) 26 (96.3) 133 (93.7) 0.53
Non-clear cell 9 (19.6) 1 (3.8) 10 (13.9) 8 (7.0) 1 (3.7) 9 (6.3)
Missing 10 3 13 4 2 6
MSKCC classification Favourable 14 (25.9) 12 (42.9) 26 (31.7) 0.12 26 (21.8) 8 (27.6) 34 (23.0) 0.68
Intermediate 19 (35.2) 11 (39.3) 30 (36.6) 51 (42.9) 13 (44.8) 64 (43.2)
Poor 21 (38.9) 5 (17.9) 26 (31.7) 42 (35.3) 8 (27.6) 50 (29.6)
No. of previous
treatment lines
1 27 (48.2) 11 (37.9) 38 (44.7) 0.18 62 (52.1) 11 (37.9) 73 (49.3) 0.32
2 25 (44.6) 12 (41.4) 37 (43.5) 36 (31.1) 10 (34.5) 46 (31.1)
3 4 (7.1) 6 (20.7) 10 (11.8) 21 (17.6) 8 (27.6) 29 (19.6)
MSKCC, Memorial Sloan-Kettering Cancer Center.
a In cohort B, patients with pneumonitis had prior nephrectomy more often than patients without pneumonitis (P Z 0.03).
Fig. 1. KaplaneMeier survival curves for patients with pneumonitis, (A) overall survival and (B) progression-free survival in cohort A;
(C) overall survival and (D) progression-free survival in cohort B.
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PFS (HR 0.53, 0.38e0.73, P < 0.001). Other potential
factors associated with OS and PFS are shown in
Supplementary Tables 1A and B.
The CBR was 57.1% (16/28) and 79.3% (23/29) in
patients with pneumonitis as compared to 24.1% (13/54)
and 39.5% (47/119) in patients with no pneumonitis, in
cohorts A and B, respectively (P Z 0.004) (P < 0.001).
3.3. Multivariate analyses
To investigate the independent association of pneumo-
nitis on outcome, we performed a multivariate survival
analysis adjusted for age, gender, number of previous
treatment lines and MSKCC risk classification for pre-
viously treated patients. In the analyses pneumonitis was
significantly associated with both longer OS (cohort A:
HR, 0.22; 95% CI 0.12e0.44; P < 0.001; cohort B: HR
0.58; 95% CI 0.36e0.94; P Z 0.03) and PFS (cohort A:
HR 0.37; 95% CI 0.21e0.66; P Z 0.001; cohort B: HR
0.61; 95% CI 0.39e0.95; P Z 0.03).
A multivariate logistic regression analysis was per-
formed in both groups to ascertain the effects of age,
gender, MSKCC risk classification and pneumonitis on
the CBR. In cohort A, patients with pneumonitis were
4.11 times more likely to have clinical benefit to ever-
olimus as compared to patients with no pneumonitis
during treatment (odds ratio [OR] 4.11; 95% CI
1.42e11.95; P Z 0.01). In cohort B patients with
pneumonitis were 5.65 times more likely to have clinical
benefit as best response as compared to patients with no
pneumonitis during treatment (OR 5.65; 95% CI
2.10e15.18; P Z 0.001).
To control for potential lead-time bias, we performed
a multivariate survival analysis with pneumonitis as a
time-dependent covariate. For this purpose, we com-
bined the two patient cohorts into one (N Z 233). In a
Cox regression model adjusted for age, gender, cohort,
number or previous treatment lines and MSKCC risk
classification for previously treated patients, CT-verified
pneumonitis was independently associated with longer
OS (HR, 0.67; 95% CI 0.46e0.97; P Z 0.03).Table 2
Overall survival, progression-free survival and clinical benefit rate for pati
with no pneumonitis/pneumonia (cohort B).
N Overall survival P
Median (95% CI) HR (95% CI)
No pneumonitis/
pneumonia
94 5.2 (3.5e6.9) 1.00 Reference
Pneumonitis/
Pneumonia
25 8.7 (4.8e12.7) 0.78 (0.49e1.25) 0.30
CT verified
pneumonitis
29 12.9 (8.9e16.8) 0.54 (0.33e0.87) 0.01 (a0.24)
CI, confidence interval; HR, hazard ratio; CT, computed tomography; PR
a P-values comparing CT-verified pneumonitis and pneumonitis/pneumo3.4. Landmark analysis
After excluding patients who progressed or died before
the landmark time point, 160 patients were included in
the landmark analysis. In the analysis, CT-verified
pneumonitis (N Z 30, 18.8%) was associated with
longer OS (17.4 months [95% CI 5.4e29.5] versus 7.8
months [95% CI 6.1e9.5]; P Z 0.01).
3.5. Subgroup analyses
To further elucidate the nature of pneumonitis we
divided patients in cohort B into three groups: Patients
with pneumonitis verified by CT (N Z 29), patients with
clinical symptoms of pneumonitis/pneumonia (N Z 25)
and patients with no clinical or radiological signs of
pneumonitis/pneumonia (N Z 94). These groups were
evenly balanced regarding baseline clinical factors, but
patients with CT-verified pneumonitis and patients with
clinical symptoms of pneumonitis/pneumonia were more
likely to have prior nephrectomy (93.1% and 88.0%;
respectively) versus no pneumonia/pneumonitis (71.3%;
P < 0.001).
Results regarding OS, PFS and CBR for the three
groups are shown in Table 2. Interestingly, there was no
statistically significant difference in OS (P Z 0.24), PFS
(P Z 0.96) or CBR (P Z 0.37) between patients with
CT-verified pneumonitis and patients with clinical
symptoms of pneumonitis/pneumonia.
4. Discussion
To the best of our knowledge, this is the first study to
establish a favourable association between pneumonitis
and everolimus treatment in all efficacy end-points
(PFS, OS and CBR) and to validate the findings in an
independent patient cohort. In patients with CT-verified
pneumonitis, OS and PFS were significantly longer.
Patients without CT-verified pneumonitis were more
than four times more likely to have progressive disease
as their best response as compared to patients with
pneumonitis. Pneumonitis remained significantlyents with verified pneumonitis, pneumonitis/pneumonia and patients
Progression-free survival P Clinical
benefit rate
P
Median (95% CI) HR (95% CI) PR þ SD %
2.8 (2.7e2.8) 1.00 Ref. 31.9 Ref.
5.6 (3.5e7.8) 0.48 (0.30e0.78) 0.003 68.0 0.002




, partial response; SD, stable disease.
nia.
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baseline clinical factors. The implication is that CT-
verified pneumonitis may serve as a biomarker of
treatment efficacy in mRCC patients treated with
everolimus.
Previous research in mRCC patients treated with
VEGF targeted therapies has demonstrated that certain
mechanism-based treatment-related adverse events, i.e.
hypertension, neutropenia and thrombocytopaenia,
reflect on-target effects and correlate with clinical effi-
cacy [20e23]. The incorporation of these biomarkers
into clinical practice may provide support in clinical
decision-making, when considering whether a given
treatment should be continued. Thus, pneumonitis may
serve as a biomarker during everolimus therapy. For
mTOR-inhibitors, such surrogate markers of treatment
efficacy have not previously been defined. The patho-
genesis of mTOR-inhibitorerelated pneumonitis, how-
ever, remains unknown. A study investigating sirolimus-
associated pneumonitis displayed lymphocytic alveolitis
with increased amounts of CD4-positive lymphocytes in
bronco alveolar lavage fluid, suggesting a cell-mediated
autoimmune response [13]. Similar findings have been
published regarding methotrexate-induced pneumonitis
[24]. Other pathogenic mechanisms include T-cell
mediated delayed-type hypersensitivity and dose-related
effects [13,14]. Precise underlying mechanisms, whereby
mTOR-inhibitor treatment leads to pneumonitis, and
especially how this leads to clinical benefit, are yet to be
elucidated and require further investigation.
Atkinson et al. previously reported that pneumonitis
was associated with longer OS in patients with mRCC
treated with everolimus/temsirolimus [16]. However,
PFS and response rates were not reported. Dabydeen
et al. demonstrated that mean tumour shrinkage and SD
by RECIST were significantly higher in patients with
pneumonitis, but did not report PFS or OS results [15].
Our data are in line with these preliminary results and
confirm the intriguing finding of improved outcome in
patients who develop pneumonitis. Despite early onset
of pneumonitis (median 2.4 and 2.8 months), we
controlled for potential time bias as patients that benefit
from treatment will be treated for a longer period and
therefore have a higher chance of developing pneumo-
nitis; the Cox regression analysis using pneumonitis as a
time-dependent covariate showed pneumonitis as an
independent predictor of improved OS. Furthermore, a
landmark analysis, controlling for early deaths and
thereby lower chance of developing pneumonitis,
demonstrated that pneumonitis was significantly asso-
ciated with longer OS. The landmark method has some
limitations, most importantly, loss of power due to
omission of early events and dependence on the choice
of the landmark time. However, given that both
methods showed similar results for OS consistent with
the primary analyses, it is unlikely that our results were
impacted by time bias.The incidence of CT-verified pneumonitis was 34.1%
and 19.6% in cohorts A and B, respectively. Previously
reported incidence of pneumonitis in patients with
mRCC varies between 13.5% and 48.7% [10,11,25]. This
wide variation in reported incidence might be due to the
often non-specific radiological appearance and clinical
symptoms of mTOR-inhibitorerelated pneumonitis
resulting in underreporting this adverse event. In addi-
tion, many of the studies have relatively few patients. A
meta-analysis (N Z 2233) of published randomised
prospective trials in breast cancer, neuroendocrine tu-
mours and mRCC reported an all grade pulmonary
toxicity of only 10.4% among patients treated with
mTOR-inhibitors [26]. In our smaller study, we
observed a higher incidence of pneumonitis in two in-
dependent consecutive patient cohorts using a rigorous
approach, emphasising the importance of evaluating the
implementation of new therapies in a real-world setting.
Nonetheless, we recognise this as a limitation in our
study, since differentiating pneumonitis from other
incidental interstitial lung diseases as well as from early
signs of infection (e.g. viral pneumonia) can be difficult.
However, when comparing the results of the subgroup
analysis performed in cohort B, there was no significant
difference in outcome between patients with CT-verified
pneumonitis and patients with clinical symptoms of
pneumonitis/pneumonia, and both subgroups had
longer PFS and higher CBR than the patients without
evidence of pneumonitis/pneumonia. In consideration of
the difficulty in differentiating pneumonitis from other
diseases of the lung parenchyma, we find the implica-
tions of these subgroup analyses clinically relevant and
in support of our notion.
Other potential limitations of our study were that the
patient cohorts represent a heterogeneous group of pa-
tients including different histological variants of RCC.
Additionally, data were lacking regarding different
radiologic patterns of pneumonitis, concomitant medi-
cation and comorbidities, including pre-existing pul-
monary dysfunction possibly predisposing patients to
pneumonitis. Although retrospective in nature, our
study was based on consecutive patients in two inde-
pendent patient cohorts.
Previous research on transplant recipients receiving
mTOR-inhibitors, has shown that pneumonitis is rela-
tively unaggressive and reversible on drug discontinua-
tion, although more severe lung toxicity may
infrequently occur [14,27]. The RECORD-1 (REnal Cell
cancer treatment with Oral RAD001 given Daily) trial
demonstrated that most cases of pneumonitis were
manageable and may be resolved by dose reduction or
treatment withdrawal, or corticosteroid administration
[10]. Recent reviews addressing the issues regarding
management of mTOR-inhibitoreassociated pneumo-
nitis, suggested that everolimus treatment can be
continued, or temporarily interrupted, among patients
with mild symptoms (grades I to II). Corticosteroids,
P. Penttilä et al. / European Journal of Cancer 81 (2017) 9e16 15and occasionally antibiotics, may be used for trouble-
some symptoms if dose alteration proves ineffective.
Even in more severe cases of pneumonitis (grade III),
reintroduction of everolimus after treatment interrup-
tion is a viable option [28,29]. Our clinical practice and
experience is in line with these recommendations.
We conclude that everolimus-induced pneumonitis is
associated with improved outcome in patients with
mRCC and may serve as a biomarker of everolimus
efficacy.
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